SynthesisMedical mycology2024
Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list.
Synthesis in Medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Population genomics reveals a long-term increase in azole resistance associated with the emerging cluster AZR amongEmerging microbes & infections · 2026Article
- Review
- Persistent Non-Journal of fungi (Basel, Switzerland) · 2026Article
- A Cationic Supramolecule With Potent Antifungal Activity, Single-Species Selectivity, and Strong Synergy With Echinocandins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- WHO Critical- and High-Priority Fungal Pathogens Beyond Human Medicine: Expanding One Health Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- Species-specific antifungal resistance trends in yeast bloodstream isolates causing candidemia before, during, and after the COVID-19 pandemic: insights from the INVIFAR Mexican multicenter network.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Integrated Genomic and Phenotypic Analyses Reveal Convergent Resistance Patterns in Clinical Candida tropicalis Isolates.Mycoses · 2026Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- Species distribution and antifungal susceptibility of Candida isolates from sterile body sites: a 14-year retrospective study at a tertiary care hospital in China (2010-2023).BMC microbiology · 2026Observational
- Draft genome sequences of two clinical isolates ofMicrobiology resource announcements · 2026Article
- Non-Life (Basel, Switzerland) · 2026Article
- Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology.Current microbiology · 2026Review
- Graphene Oxide Composites with Ultrahigh-Molecular-Weight Polyethylene for Innovative Prostheses for Arthroplasty.ACS applied bio materials · 2026Article
- Misdiagnosis of invasive pulmonary fungal disease caused by drug-resistantFrontiers in medicine · 2026Article
- Culture-based analysis of oral dysbiosis in post-oncological patients rehabilitated with obturator prostheses.Journal of oral microbiology · 2026Article
- Article
- Article
- Retrospective Multicenter Study on Invasive Candidiasis in Türkiye Demonstrates High Genetic Variety of Candida tropicalis.Mycopathologia · 2025Article
- Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.Scientific reports · 2025Article
- Fluconazole-resistant vulvovaginal candidiasis in reproductive-age women: a study from Himalayan country.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
In response to the growing global burden of fungal infections with uncertain impact, the World Health Organization (WHO) established an Expert Group to identify priority fungal pathogens and establish the WHO Fungal Priority Pathogens List for future research. This systematic review aimed to evaluate the features and global impact of invasive candidiasis caused by Candida tropicalis. PubMed and Web of Science were searched for studies reporting on criteria of mortality, morbidity (defined as hospitalization and disability), drug resistance, preventability, yearly incidence, diagnostics, treatability, and distribution/emergence from 2011 to 2021. Thirty studies, encompassing 436 patients from 25 countries were included in the analysis. All-cause mortality due to invasive C. tropicalis infections was 55%-60%. Resistance rates to fluconazole, itraconazole, voriconazole and posaconazole up to 40%-80% were observed but C. tropicalis isolates showed low resistance rates to the echinocandins (0%-1%), amphotericin B (0%), and flucytosine (0%-4%). Leukaemia (odds ratio (OR) = 4.77) and chronic lung disease (OR = 2.62) were identified as risk factors for invasive infections. Incidence rates highlight the geographic variability and provide valuable context for understanding the global burden of C. tropicalis infections. C. tropicalis candidiasis is associated with high mortality rates and high rates of resistance to triazoles. To address this emerging threat, concerted efforts are needed to develop novel antifungal agents and therapeutic approaches tailored to C. tropicalis infections. Global surveillance studies could better inform the annual incidence rates, distribution and trends and allow informed evaluation of the global impact of C. tropicalis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.